🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

MabVax Therapeutics Holdings Inc (MBVXQ)

OTC Markets
Currency in USD
Disclaimer
0.023
0.000(0.00%)
Closed
Fair Value
Day's Range
0.0200.023
52 wk Range
0.0000.023
Prev. Close
0.021
Open
0.02
Day's Range
0.02-0.023
52 wk Range
0-0
Volume
0
Average Volume (3m)
134,483
1-Year Change
0%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
MBVXQ Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Currently not supported.
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

MabVax Therapeutics Holdings Inc Company Profile

On March 20, 2020, MabVax Therapeutics Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company’s product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company’s HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.